Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Financing Activities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Cash from Financing Activities for 4 consecutive years, with $76.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 408.13% to $76.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $89.6 million, a 1879.24% increase, with the full-year FY2024 number at $29.2 million, down 36.88% from a year prior.
  • Cash from Financing Activities was $76.4 million for Q3 2025 at Orchestra BioMed Holdings, up from -$428000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $86.1 million in Q2 2022 to a low of -$10.7 million in Q4 2023.
  • A 4-year average of $17.0 million and a median of $86000.0 in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 375775.0% in 2024, then tumbled 1744.44% in 2025.
  • Orchestra BioMed Holdings' Cash from Financing Activities stood at -$5.1 million in 2022, then tumbled by 110.14% to -$10.7 million in 2023, then surged by 230.39% to $13.9 million in 2024, then surged by 447.77% to $76.4 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Cash from Financing Activities are $76.4 million (Q3 2025), -$428000.0 (Q2 2025), and -$296000.0 (Q1 2025).